SAN FRANCISCO, California (January 12, 2026) — Grove AI, a leader in agentic AI for pharma R&D and clinical trial operations, today announced that it has been acquired by Hippocratic AI, the global leader in patient-facing generative AI healthcare agents. The acquisition unites two organizations aligned around a shared vision of healthcare abundance, expanding access, accelerating research, and removing friction across the life sciences value chain.

Over the past year, Grove AI has powered more than 10 million patient interactions across complex research and development workflows for life sciences enterprises, including two of the top five global pharmaceutical companies. With the scale, expertise, and technology at Hippocratic AI, Grove AI will advance its mission to eliminate manual bottlenecks and raise the standard for AI-driven execution, while remaining deeply aligned with responsible, high-trust agentic AI in life sciences.

Grove AI extends gratitude to its customers and partners for entrusting the company with their most critical processes, and to its employees, investors, and advisors, whose belief and dedication made this milestone possible. Grove AI will continue delivering trusted, enterprise-grade solutions to the life sciences industry as part of Hippocratic AI.

To learn more, read Fierce Healthcare's coverage on the acquisition here.